Skip to main content
SpringerLink
Log in

Treatment of Relapsed and Refractory AML with Mitoxantrone and Etoposide: A Study of the Eastern Cooperative Oncology Group

  • Conference paper
Acute Leukemias IV

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 36))

Abstract

The treatment of relapsed and refractory AML remains unsatisfactory. It has generally been assumed that, for such patients, the possibility of long-term disease-free survival when treated with chemotherapy is almost negligible. The main focus of therapy rests with attempts to optimize the likelihood of achieving a complete remission (CR) and then either prolong the CR [l] or attempt to induce a long-term disease-free survival using some form of intensive chemotherapy or bone marrow transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cassileth PA, Harrington DP, Hines JD et al. (1988) Maintenance chemotherapy prolongs initial complete remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 6: 583–589

    PubMed  CAS  Google Scholar 

  2. Double JC, Brown JR (1976) Evaluation of the binding of some substituted anthraquinones and naphthacenequinones to DNA. J Pharm Pharmacol 28: 166–169

    Article  PubMed  CAS  Google Scholar 

  3. ZE-Cheng RKY, Cheng CC (1974) Antineoplastic agents. Structure and activity relationship study of bis (substituted aminoalkylamino (anthraQuinones). J Med Chern 21: 291–294

    Article  Google Scholar 

  4. Arlin Z, Silver R, Cassileth PA et al. (1984) Phase I/II trial of mitoxantrone in acute leukemia. Cancer Treat Rep 69: 61–64

    Google Scholar 

  5. Moore JO, Olsen GA (1984) Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Semin Oncol 11(3): 41–46

    PubMed  CAS  Google Scholar 

  6. Paciucci PA, Cuttner J, Holland JS (1984) Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Semin Oncol 11 (3): 36–40

    PubMed  CAS  Google Scholar 

  7. Van Echo DA, Wiernik PH, Aisner J (1980) High-dose VP-16-213 for the treatment of patients with previously treated acute leukemia. Can Clin Trials 3(4): 325–328

    Google Scholar 

  8. Bennett JM, Lymann GM, Cassileth PA et al. (1984) A phase II trial of VP-16 in adults with refractory acute myeloid leukemia. An ECOG study. Am J Clin Oncol (CCT) 7: 471–473

    Article  CAS  Google Scholar 

  9. Rowe JM, Mazzan JJ, Hines JD et al. (1990) Mitoxantrone and etoposide in patients with relapsed and refractory acute non-lymphocytic leukemia. Acute Leukemias II ed. Buchner et al. In Hematology and Blood Transfusion 33: 326–329, Springer-Verlag, Berlin Heidelberg

    Google Scholar 

  10. Rowe JM, Oken MM, Cassileth PA et al. (1992) Clinical trials in adults with relapsed and refractory acute myelogenous leukemia. The ECOG and University of Rochester experience. Acute Leukemias III ed. Hiddemann et al. In Hematology and Blood Transfusion 34: 392–395, Springer-Verlag, Berlin, Heidelberg

    Google Scholar 

  11. Cassileth PA, Begg CB, Bennett JM et al. (1984) A randomized study of efficacy of consolidation therapy in adult acute non-lymphocytic leukemia. Blood 63(4): 843–847

    PubMed  CAS  Google Scholar 

  12. Oken MM, Creech R, Tormey D et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–653

    Article  PubMed  CAS  Google Scholar 

  13. Ho Ad, Lipp T, Ehninger G et al. (1988) Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia – an active and well tolerated regimen. J Clin Oncol 6(2): 213–217

    PubMed  CAS  Google Scholar 

  14. Lazzarino M, Morra E, Alessandrino EP (1988) Mitoxantrone-etoposide combination chemotherapy for relapsed and refractory acute myeloid leukemia (AML) in adults. Blood 72(5): 210a (abstr)

    Google Scholar 

  15. Hiddemann W, Buchner T (1990) Treatment strategies for relapsed acute myeloid leukemia - a proposal based on the definition of refractoriness against conventional chemotherapy (1990) in Acute Myelogenous Leukemia: Progress and Controversies ed. Gale RP, Wiley-Liss, Inc. 363–373

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Unit, University of Rochester Medical Center, Rochester, NY, USA

    J. M. Rowe

  2. Dana Farber Cancer Institute, Boston, MA, USA

    J. W. Andersen

  3. Marshfield Clinic, Marshfield, WI, USA

    J. J. Mazza

  4. Cleveland Metropolitan Hospital, Cleveland, OH, USA

    J. D. Hines

  5. Cancer Center, University of Rochester Medical Center, Rochester, NY, USA

    J. M. Bennett

  6. Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

    P. A. Cassileth

  7. Case Western Reserve University, Cleveland, OH, USA

    E. Mansour

  8. Virginia Piper Cancer Institute, Minneapolis, MN, USA

    M. M. Oken

Authors
  1. J. M. Rowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. W. Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. J. Mazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. D. Hines
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. M. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. A. Cassileth
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Mansour
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. M. Oken
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, Germany

    T. Büchner

  2. Department of Pediatrics, University of Münster, Albert-Schweitzer-Strasse 33, 48145, Münster, Germany

    G. Schellong  & J. Ritter  & 

  3. Department of Internal Medicine, University of Göttingen, Robert-Koch-Strasse 40, 37075, Göttingen, Germany

    W. Hiddemann  & B. Wörmann  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Rowe, J.M. et al. (1994). Treatment of Relapsed and Refractory AML with Mitoxantrone and Etoposide: A Study of the Eastern Cooperative Oncology Group. In: Büchner, T., Hiddemann, W., Wörmann, B., Schellong, G., Ritter, J. (eds) Acute Leukemias IV. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 36. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78350-0_40

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78350-0_40

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-78352-4

  • Online ISBN: 978-3-642-78350-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation